PMID- 30386800
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2322-4436 (Print)
IS  - 2322-3219 (Electronic)
IS  - 2322-3219 (Linking)
VI  - 7
IP  - 3
DP  - 2018 Fall
TI  - Regulatory T Cells and Ocular Graft Versus Host Disease: A Novel Treatment 
      Approach.
PG  - 119-121
AB  - Graft Versus Host Disease (GVHD) is an inflammatory immune disease, mediated by 
      the donor's immune cells and can arise after allogeneic Hematopoietic Stem Cell 
      Transplantation (HSCT) for the treatment of hematologic malignancies. It can lead 
      to destructive manifestations in various tissues, particularly dermatological, 
      gastrointestinal, and ocular tissues. The most common ocular morbidity is dry 
      eyes, which is often the first manifestation of GVHD. Regulatory T cells (Tr) can 
      be broadly classified as natural or adaptive (induced). After Bone-Marrow 
      Transplantation (BMT), excessively increased levels of type 1 Tr (Tr1) are 
      generally observed with absence of a GVHD, while low levels are seen with severe 
      GVHD. Treatment of patients, undergoing BMT with Interleukin-10 (IL-10)-anergized 
      donor T cells, led to immune reconstitution without the development of GVHD, 
      which resulted in protection against infection and against the return of the 
      cancer. Surprisingly, in both naive syngeneic mouse models of skin and cardiac 
      allografts, graft retention was augmented after infusion of in vitro generated 
      double-negative Tr (DN Tr). In addition, GVHD was reduced in mice with a genetic 
      deficiency in the IL-27 receptor (IL-27R-/-) and in mice treated with 
      anti-IL-27p28-specific antibody. Considering above mentioned findings we would 
      suggest carrying out experiments, using animal models of GVHD, in order to 
      evaluate the potential role of Tr, as an innovative approach to overcome severe 
      ocular morbidity caused by ocular GVHD.
FAU - Pishnamaz, Mohammad Reza
AU  - Pishnamaz MR
AD  - Optometry Department, Iran University of Medical Sciences, Tehran, Iran.
FAU - Jafarzadehpour, Ebrahim
AU  - Jafarzadehpour E
AD  - Optometry Department, Iran University of Medical Sciences, Tehran, Iran.
FAU - Pishnamaz, Razieh
AU  - Pishnamaz R
AD  - Department of Allergy and Immunology, Mashhad University of Medical Sciences, 
      Mashhad, Iran.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Hypothesis Discov Innov Ophthalmol
JT  - Medical hypothesis, discovery & innovation ophthalmology journal
JID - 101611331
PMC - PMC6205679
OTO - NOTNLM
OT  - Anti-IL-27p28-Specific Antibody
OT  - Graft vs Host Disease
OT  - IL-27 Receptor
OT  - Regulatory
OT  - T-Lymphocytes
COIS- Ethical issues have been completely observed by the authors. All named authors 
      meet the International Committee of Medical Journal Editors (ICMJE) criteria for 
      authorship of this manuscript, take responsibility for the integrity of the work 
      as a whole, and have given final approval for the version to be published. No 
      conflict of interest has been presented.
EDAT- 2018/11/06 06:00
MHDA- 2018/11/06 06:01
PMCR- 2018/09/01
CRDT- 2018/11/03 06:00
PHST- 2018/11/03 06:00 [entrez]
PHST- 2018/11/06 06:00 [pubmed]
PHST- 2018/11/06 06:01 [medline]
PHST- 2018/09/01 00:00 [pmc-release]
AID - mehdiophth-7-119 [pii]
PST - ppublish
SO  - Med Hypothesis Discov Innov Ophthalmol. 2018 Fall;7(3):119-121.